Radioimmunotherapy (RIT) Applied to HL – a Useful Tool?
Tim Illidge
Yttrium-90 Radiolabeled Humanized Anti- CD25 Monoclonal Antibody, Daclizumab Provides Effective Therapy for Refractory and Relapsed HL
Thomas Waldmann
Involved Node Radiotherapy: Impact on Dose to PTV and Organs at Risk
Bart Reymen
Chemotherapy Alone versus Chemotherapy Plus Radiotherapy for Early Stage HL
Fareed A. Rehan
10:30 – 12:00
Room: Großer Saal
Scientific SessionAllogenetic Transplantation
Christian Gisselbrecht
Aaron Polliack
Overview on Transplantation Strategies
Norbert Schmitz
Do we Need Allogeneic Transplantation in HL?
John Gribben
New Frontiers in Allogeneic Transplantation for HL
Paolo Anderlini
Reduced Intensity Allogeneic Stem Cell Transplantation (RIC-Allo) for Refractory / Relapsed HL. Preliminary Results of an EBMT Prospective Trial
Anna Sureda
Workshop Report
Christian Gisselbrecht
12:15 – 13:45
Room: Großer Saal
Satellite Symposium
(by Lilly Deutschland GmbH)
Role of Gemcitabine in the Treatment of Hodgkins Lymphoma
Anas Younes
Development of Gemcitabine in HL – US Perspective
George Canellos
Development of Gemcitabine in HL – European Perspective
Henning Bredenfeld
New Perspectives in the Treatment of HL
Peter Borchmann
Lilly Oncology Pipeline
Marjo Hahka-Kemppinen
Eli Lilly
14:00 – 15:30
Room: Großer Saal
Scientific SessionPET
Magnus Björkholm
Anton Hagenbeek
PET-CT for Treatment Response Assessment in Lymphoma
Sigrid Stroobants
PET for Early Response Adapted Therapy
Martin Hutchings
Current Role and Future of PET in HL
Bruce Cheson
FDG-PET for Assessment of Residual Tissue after Completion of Chemotherapy in HL – Report on the 2nd Interim Analysis of the PET Investigation in the Trial HD15 of the GHSG
Carsten Kobe
Early Interim FDG-PET Overshadows the Prognostic Role of IPS in Advanced-stage HL Treated by Conventional ABVD Therapy
Andrea Gallamini
Interim Results of a UK NCRI Randomised Trial Comparing Involved Field Radiotherapy with No Further Treatment after 3 Cycles ABVD and a “Negative” PET Scan in Clinical Stages IA/IIA
John Radford
16:00 – 17:30
Room: Großer Saal
Scientific SessionAdvanced Stages HL
Richard Fisher
Mads Hansen
North America: Cooperative Groups
Sandra Horning
EORTC
Patrice Carde
GHSG
Volker Diehl
Phase-II Study of Rituximab Plus ABVD for the Treatment of Newly Diagnosed Patients with Advanced Stage Classical HL
Anas Younes
High-dose Therapy and ASCT versus Conventional Therapy for Patients with Advanced HL Responding to Front-line Therapy: Long Term Results
Angelo Michele Carella
ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the Initial Treatment of Patients with Advanced HL. Preliminary Results of HD2000 GISL Trial